Background:Pharmacological blockade of the renin-angiotensin-aldosteron system ameliorates glomerular and tubulointerstitial damage. For optimal renoprotection, high doses of angiotensin II converting enzyme inhibitors and angiotensin II subtype 1 receptor antagonists are commonly recommended, but cannot always be administered. The aim of this study was to evaluate the effects of low-dose (25 mg) losartan on proteinuria and tubular injury extent.Material/Methods:This was an open, randomized, 12-month study on the effects of 25 mg of losartan (n=19) vs. 10 mg of enalapril (n=14) as a control on proteinuria, urinary excretion of N-acetyl- β -D-glucosaminidase (NAG), and blood pressure in patients with primary glomerulonephritis. The second part of the study was an uncontrolled assessment of the renal effects of 50-mg administration of losartan.Results:There were no significant differences between the groups in the effects on proteinuria and NAG excretion. Losartan and enalapril reduced proteinuria by 32.8% (p

Keywords: Angiotensin II Type 1 Receptor Blockers - therapeutic use, Angiotensin-Converting Enzyme Inhibitors - therapeutic use, Anti-Arrhythmia Agents - therapeutic use, Blood Pressure, Creatinine - blood, enalapril, Glomerulonephritis - drug therapy, Kidney Tubules - pathology, Losartan - therapeutic use, Proteinuria - prevention & control